The cIMPACT-NOW updates and their significance to current neuro-oncology practice

L Nicolas Gonzalez Castro; Pieter Wesseling

doi:10.1093/nop/npaa055

The cIMPACT-NOW updates and their significance to current neuro-oncology practice

Neurooncol Pract. 2020 Aug 29;8(1):4-10. doi: 10.1093/nop/npaa055. eCollection 2021 Feb.

Authors

L Nicolas Gonzalez Castro^{1

2

3}, Pieter Wesseling^{4

5}

Affiliations

¹ Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
² Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
³ Harvard Medical School, Boston, Massachusetts, USA.
⁴ Department of Pathology, Amsterdam University Medical Centers/VUmc/Brain Tumor Center Amsterdam, the Netherlands.
⁵ Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Abstract

Over the past 4 years, advances in molecular pathology have enhanced our understanding of CNS tumors, providing new elements to refine their classification and improve the 2016 World Health Organization (WHO) Classification of CNS tumors. The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official WHO (cIMPACT-NOW) was formed in late 2016 by a group of neuropathology and neuro-oncology experts to provide practical recommendations (published as cIMPACT-NOW updates) to improve the diagnosis and classification of CNS tumors, in advance of the publication of a new WHO Classification of CNS tumors. Here we review the content of all the available cIMPACT-NOW updates and discuss the implications of each update for the diagnosis and management of patients with CNS tumors.

Keywords: IDH-mutant gliomas; brain tumor classification; cIMPACT-NOW; glioblastoma; molecular pathology.

© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Publication types

Review